Company news
Hemostemix Inc news in 2022
Hemostemix Inc's news releases, calls and decks from 2022, newest first.
Hemostemix Issued 'Your Fountain of Youth' Trademark by Cyprus
December 8, 2022
Hemostemix Thanks Neim Malo, Beefstro's Founder, for His ACP-01 Testimonial Interview
November 30, 2022
Hemostemix Thanks Six-Time Grammy Award Winner, Howie Lindeman, for his ACP-01 Testimonial Interview
November 17, 2022
Hemostemix Announces Advancements in Its Automation of Production
November 15, 2022
Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials
October 26, 2022
Hemostemix Announces Presentation to the Emerging Growth Conference
October 25, 2022
Hemostemix Announces NCP-01 Study to Address a $10 Billion Pain Market
October 19, 2022
Hemostemix Announces Exploring Clinical Trial Financing Alternatives
October 4, 2022
Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board
September 27, 2022
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board
September 20, 2022
Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
September 16, 2022
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
September 15, 2022
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board
September 14, 2022
Hemostemix Announces Its Presentation to the Emerging Growth Conference
September 14, 2022
Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.
September 13, 2022
Hemostemix Announces A Clarification
August 31, 2022
Hemostemix Announces Phase II Results Plus New Heart Study Demonstrating Statistically Significant Improvement in Ejection Fraction at 4 and 12 Months after ACP-01 Heart Injections
August 30, 2022
Hemostemix Announces Closing of UNIT Private Placement
August 22, 2022
Hemostemix Announces Closing of Second Tranche of UNIT Private Placement
August 12, 2022
Hemostemix Announces the Incorporation of PreCerv Inc. And a Global Field of Use License to NCP-01
June 14, 2022
Hemostemix Announces Financing
May 19, 2022
Hemostemix Announces Pete Pavlin, P.Eng., Vice-President Operations
May 19, 2022
Hemostemix Announces Rick Groome as Special Advisor to The CEO
May 16, 2022
Hemostemix Announces Its Intellectual Property is Back Home
May 10, 2022
Hemostemix Announces Closing of $2,750,000
April 25, 2022
Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed
April 12, 2022
Hemostemix Announces Settlement Agreement
March 23, 2022
Hemostemix: Interest Payment on Convertible Debenture
March 3, 2022
Hemostemix Announces $2,750,000 Convertible Debenture
March 2, 2022
Hemostemix Announces Stock Options Grant
March 1, 2022
Your Fountain of Youth Trademarked by Hemostemix
February 14, 2022
Hemostemix Partners with My Next Health, Obtains USD $150,000 Subscription at CAD $0.25 Per Unit, and Incorporates Functional Genomics
January 21, 2022
Hemostemix to Combine ACP-01 with Dr. James Shapiro's Islet Cells to Treat Type 1 Diabetes
January 11, 2022
Decks in 2022
- Investor Presentation (March 2022)
Investor deck · 18 slides · Mar 29, 2022
- Non-Deal Roadshow (February 2022)
Roadshow · 14 slides · February 2022